omeprazole
Term · Oncology and biomedicine · MLC-T-ONC-006061
A drug that inhibits gastric acid secretion.
A benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic activities and does not antagonize histamine H2 receptors.
| Identifier | MLC-T-ONC-006061 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | OMEP |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-006061",
"term": "omeprazole",
"field": "Oncology and biomedicine",
"definitions": [
"A drug that inhibits gastric acid secretion.",
"A benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic activities and does not antagonize histamine H2 receptors."
],
"abbreviation": "OMEP",
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/omeprazole/"
}
Record 12,170 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.